American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

2021 ◽  
Author(s):  
Archit B Baskaran ◽  
Priya Kumthekar ◽  
Amy B Heimberger ◽  
Rimas V Lukas
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Case Series ◽  
Primary Brain Tumor ◽  
Phase Iii ◽  
Future Research ◽  
Csf Biomarkers ◽  
Phase Ii Trials ◽  
Tumor Management ◽  
American Society

In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.

Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications

2008 ◽  
Vol 26 (13) ◽  
pp. 2205-2211 ◽  
Author(s):  
Vincent C. Tam ◽  
Sebastien J. Hotte
Keyword(s):  
Clinical Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Full Text ◽  
Statistical Significance ◽  
Phase Iii ◽  
Inclusion Criteria ◽  
Phase Iii Clinical Trial ◽  
End Point ◽  
American Society

Purpose This study aimed to determine the consistency of phase III clinical trial abstracts presented at American Society of Clinical Oncology (ASCO) Annual Meetings compared with their subsequent full-text publications. Methods We identified abstracts describing phase III clinical trials of chemotherapy, chemoradiotherapy, immunotherapy, and hormone therapy presented at the 36th ASCO Annual Meeting in May 2000. We searched MEDLINE and PubMed for all corresponding publications. Data were extracted from the abstracts and publications that met our inclusion criteria. Results A total of 192 abstracts were identified. Seventy-four abstracts met our inclusion criteria. Six years after the 2000 ASCO Meeting, 74% of abstracts had corresponding publications. The primary end point was stated in 34% of abstracts and 100% of published papers. The primary end point result differed by more than 5% between the abstract and publication in 42% of comparisons. The statistical significance of the primary end point and study conclusions were consistent between abstracts and subsequent publications in 89% and 91% of the comparisons, respectively. Abstracts selected as plenary or oral presentations were significantly more likely to be published. No factors predicted consistency for primary end point significance and overall conclusion between ASCO abstracts and their journal publications. Conclusion When carefully selected, ASCO Annual Meeting abstracts of phase III trials consistently reflect final published results, but some differences were observed that warrant caution in using abstract results to shape treatment decisions before full publication.

Highlights from the 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1–5, 2007

2007 ◽  
Vol 1 (5) ◽  
pp. 269-274
Author(s):  
Latha Shivakumar ◽  
Marissa Shrader ◽  
Sonia Cunningham ◽  
Jorge E. Cortés ◽  
Diane Gambill
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society

The Annual Meeting of the American Society of Clinical Oncology

2010 ◽  
Vol 3 (2) ◽  
pp. E1-E5
Author(s):  
Kristin Garcia ◽  
Aarati Ranganathan ◽  
Robert L. Coleman
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society

scholarly journals Practice Changing Results in RCC come from ASCO 2021

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Marc Matrana ◽  
Erin Pierce ◽  
Erica Doubleday
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Kidney Cancer ◽  
Medical Oncology ◽  
Great Success ◽  
Second Year ◽  
American Society

For the second year in a row, the annual meeting of the American Society of Clinical Oncology (ASCO) was held virtually due to the ongoing COVID-19 pandemic. Nonetheless, the meeting was hailed as a great success and brought much practice changing data in the field of genitourinary medical oncology, including kidney cancer.

scholarly journals Destaques da ASCO 2016 - Imunoterapia no Tratamento do Cancro do Pulmão | Rastreio do Cancro do Pulmão: Considerações Lógicas e Práticas

2018 ◽  
Author(s):  
Maria Bárbara Parente
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Immune Checkpoint ◽  
National Lung Screening Trial ◽  
American Society ◽  
Lung Screening ◽  
Screening Trial

Inibidores de immune checkpoint são uma promessa na luta contra o cancro do pulmão e outros tumores malignos, alterando o microambiente do tumor e bloqueando a evasão ao sistema imunitário. Dois anticorpos anti-PD-1, nivolumab e pembrolizumab, estão aprovados para uso clínico, no cancro do pulmão, doença avançada em segunda linha. Anticorpos PD-L1 tal como atezolizumab e MEDI-4736 estão em desenvolvimento clínico e são alvo atual de vários estudos de fase II/III inclusivamente a decorrer em Portugal; tratamento de segunda linha em doentes com cancro do pulmão de não pequenas células doença avançada tem tido até agora como opção padrão o docetaxel. Desde a publicação dos resultados do National Lung Screening Trial (NLST) em 2011, o rastreio do cancro do pulmão com tomografia computorizada de dose baixa tem sido o centro da investigação, guidelines e discussão geral deste tema. O racional para o screening tem evoluído nos últimos anos, dado que hospitais e outros sistemas de saúde ganharam experiência na implementação de programas de rastreio. O screening também mostra a importância do tabagismo, não apenas como um fator de risco para o cancro, mas também como uma variável que pode afetar drasticamente os resultados do cancro. Estas foram, entre outras, questões discutidas por Especialistas no 2016 ASCO Annual Meeting - American Society of Clinical Oncology, que decorreu em Chicago de 3 a 7 de junho de 2016. Recebido: 20/08/2016 – Aceite: 25/08/2016

Highlights from: the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA, June 2006

2006 ◽  
Vol 6 (2) ◽  
pp. 109-113
Author(s):  
Manisha Gupta ◽  
Sabeeha Muneer ◽  
Susan Peck ◽  
Edward Chu ◽  
Carlos Becerra ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
American Society
Sign in / Sign up

Export Citation Format

Share Document